119 related articles for article (PubMed ID: 16083349)
1. Neuromedin U--a new target in obesity.
Doggrell SA
Expert Opin Ther Targets; 2005 Aug; 9(4):875-7. PubMed ID: 16083349
[TBL] [Abstract][Full Text] [Related]
2. Neuromedin U has a novel anorexigenic effect independent of the leptin signaling pathway.
Hanada R; Teranishi H; Pearson JT; Kurokawa M; Hosoda H; Fukushima N; Fukue Y; Serino R; Fujihara H; Ueta Y; Ikawa M; Okabe M; Murakami N; Shirai M; Yoshimatsu H; Kangawa K; Kojima M
Nat Med; 2004 Oct; 10(10):1067-73. PubMed ID: 15448684
[TBL] [Abstract][Full Text] [Related]
3. The antiobesity effects of centrally administered neuromedin U and neuromedin S are mediated predominantly by the neuromedin U receptor 2 (NMUR2).
Peier A; Kosinski J; Cox-York K; Qian Y; Desai K; Feng Y; Trivedi P; Hastings N; Marsh DJ
Endocrinology; 2009 Jul; 150(7):3101-9. PubMed ID: 19324999
[TBL] [Abstract][Full Text] [Related]
4. Transgenic overexpression of neuromedin U promotes leanness and hypophagia in mice.
Kowalski TJ; Spar BD; Markowitz L; Maguire M; Golovko A; Yang S; Farley C; Cook JA; Tetzloff G; Hoos L; Del Vecchio RA; Kazdoba TM; McCool MF; Hwa JJ; Hyde LA; Davis H; Vassileva G; Hedrick JA; Gustafson EL
J Endocrinol; 2005 Apr; 185(1):151-64. PubMed ID: 15817836
[TBL] [Abstract][Full Text] [Related]
5. Effects of peripheral administration of a Neuromedin U receptor 2-selective agonist on food intake and body weight in obese mice.
Kaisho T; Nagai H; Asakawa T; Suzuki N; Fujita H; Matsumiya K; Nishizawa N; Kanematsu-Yamaki Y; Dote K; Sakamoto JI; Asami T; Takekawa S
Int J Obes (Lond); 2017 Dec; 41(12):1790-1797. PubMed ID: 28757640
[TBL] [Abstract][Full Text] [Related]
6. A PEGylated analog of short-length Neuromedin U with potent anorectic and anti-obesity effects.
Inooka H; Sakamoto K; Shinohara T; Masuda Y; Terada M; Kumano S; Yokoyama K; Noguchi J; Nishizawa N; Kamiguchi H; Fujita H; Asami T; Takekawa S; Ohtaki T
Bioorg Med Chem; 2017 Apr; 25(8):2307-2312. PubMed ID: 28291683
[TBL] [Abstract][Full Text] [Related]
7. Small lipidated anti-obesity compounds derived from neuromedin U.
Micewicz ED; Bahattab OS; Willars GB; Waring AJ; Navab M; Whitelegge JP; McBride WH; Ruchala P
Eur J Med Chem; 2015 Aug; 101():616-26. PubMed ID: 26204509
[TBL] [Abstract][Full Text] [Related]
8. Effects of peripherally administered neuromedin U on energy and glucose homeostasis.
Peier AM; Desai K; Hubert J; Du X; Yang L; Qian Y; Kosinski JR; Metzger JM; Pocai A; Nawrocki AR; Langdon RB; Marsh DJ
Endocrinology; 2011 Jul; 152(7):2644-54. PubMed ID: 21586559
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity of the hypothalamic paraventricular nucleus to the locomotor-activating effects of neuromedin U in obesity.
Novak CM; Zhang M; Levine JA
Brain Res; 2007 Sep; 1169():57-68. PubMed ID: 17706946
[TBL] [Abstract][Full Text] [Related]
10. Comparison of glucose tolerance between wild-type mice and mice with double knockout of neuromedin U and neuromedin S.
Ensho T; Maruyama K; Qattali AW; Yasuda M; Uemura R; Murakami N; Nakahara K
J Vet Med Sci; 2019 Sep; 81(9):1305-1312. PubMed ID: 31341114
[TBL] [Abstract][Full Text] [Related]
11. PEGylated neuromedin U-8 shows long-lasting anorectic activity and anti-obesity effect in mice by peripheral administration.
Masuda Y; Kumano S; Noguchi J; Sakamoto K; Inooka H; Ohtaki T
Peptides; 2017 Aug; 94():99-105. PubMed ID: 28400225
[TBL] [Abstract][Full Text] [Related]
12. Role of neuromedin U in accelerating of non-alcoholic steatohepatitis in mice.
Teranishi H; Hayashi M; Higa R; Mori K; Miyazawa T; Hino J; Amano Y; Tozawa R; Ida T; Hanada T; Miyazato M; Hanada R; Kangawa K; Nakao K
Peptides; 2018 Jan; 99():134-141. PubMed ID: 29017855
[TBL] [Abstract][Full Text] [Related]
13. A functional leptin system is essential for sodium tungstate antiobesity action.
Canals I; Carmona MC; Amigó M; Barbera A; Bortolozzi A; Artigas F; Gomis R
Endocrinology; 2009 Feb; 150(2):642-50. PubMed ID: 18845634
[TBL] [Abstract][Full Text] [Related]
14. Central control of bone remodeling by neuromedin U.
Sato S; Hanada R; Kimura A; Abe T; Matsumoto T; Iwasaki M; Inose H; Ida T; Mieda M; Takeuchi Y; Fukumoto S; Fujita T; Kato S; Kangawa K; Kojima M; Shinomiya K; Takeda S
Nat Med; 2007 Oct; 13(10):1234-40. PubMed ID: 17873881
[TBL] [Abstract][Full Text] [Related]
15. Neuromedin U inhibits food intake partly by inhibiting gastric emptying.
Dalbøge LS; Pedersen SL; Secher T; Holst B; Vrang N; Jelsing J
Peptides; 2015 Jul; 69():56-65. PubMed ID: 25895852
[TBL] [Abstract][Full Text] [Related]
16. Neuromedin U-deficient rats do not lose body weight or food intake.
Yokogi K; Goto Y; Otsuka M; Ojima F; Kobayashi T; Tsuchiba Y; Takeuchi Y; Namba M; Kohno M; Tetsuka M; Takeuchi S; Matsuyama M; Aizawa S
Sci Rep; 2022 Oct; 12(1):17472. PubMed ID: 36302800
[TBL] [Abstract][Full Text] [Related]
17. The neuromedin U system: Pharmacological implications for the treatment of obesity and binge eating behavior.
Botticelli L; Micioni Di Bonaventura E; Del Bello F; Giorgioni G; Piergentili A; Quaglia W; Bonifazi A; Cifani C; Micioni Di Bonaventura MV
Pharmacol Res; 2023 Sep; 195():106875. PubMed ID: 37517560
[TBL] [Abstract][Full Text] [Related]
18. Appetite-modifying actions of pro-neuromedin U-derived peptides.
Bechtold DA; Ivanov TR; Luckman SM
Am J Physiol Endocrinol Metab; 2009 Aug; 297(2):E545-51. PubMed ID: 19531638
[TBL] [Abstract][Full Text] [Related]
19. Small-Molecule Neuromedin U Receptor 2 Agonists Suppress Food Intake and Decrease Visceral Fat in Animal Models.
Sampson CM; Kasper JM; Felsing DE; Raval SR; Ye N; Wang P; Patrikeev I; Rytting E; Zhou J; Allen JA; Hommel JD
Pharmacol Res Perspect; 2018 Oct; 6(5):e00425. PubMed ID: 30151213
[TBL] [Abstract][Full Text] [Related]
20. Neuromedin U, a Key Molecule in Metabolic Disorders.
Teranishi H; Hanada R
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
